BANK VONTOBEL/CALL/ELI LILLY & CO/680/0.1/20.09.24 | Market Closed - Deutsche Boerse AG 19:02:05 28/06/2024 BST | ||
| 22.8 EUR | +3.21% |
|
| Current month | +59.89% | ||
| 1 month | +71.69% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 22.8 | +3.21% |
| 27/06/24 | 22.09 | +1.66% |
| 26/06/24 | 21.73 | -1.50% |
| 25/06/24 | 22.06 | +2.75% |
| 24/06/24 | 21.47 | +5.45% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 07:02 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VM3RDX |
| ISIN | DE000VM3RDX2 |
| Date issued | 09/10/2023 |
| Strike | 680 $ |
| Maturity | 20/09/2024 (83 Days) |
| Parity | 10 : 1 |
| Emission price | 3.23 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 22.96 € |
|---|---|
| Lowest since issue | 2.87 € |
| Spread | 0.02 € |
| Spread % | 0.09% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
905.4
USD
Average target price
868.9
USD
Spread / Average Target
-4.03%
- Stock Market
- Warrants
- Warrant
